Summary:
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Key Inclusion Criteria:
- Males or females
- 18-65 years of age at the time of Screening Visit
- Subject has at least 1-year history of migraines, with or without aura
- Must have in-tact nasal passage
Qualified Participants May Receive:
Compensation of $100 for up to three (3) completed study visits up to three (3) months + compliance bonus for e-diary completion